[메디칼업저버 박선재 기자] The results of a six-year follow-up study that showed that the addition of ADCETRIS (ingredient: brentuximab vedotin) to conventional chemotherapy for classical Hodgkin lymphoma improved overall survival (OS) was published.
As a result of this study, interest is growing whether Takeda Pharmaceutical’s ADCETRIS (ingredient name: brentuximab vedotin), an antibody drug conjugate, can be established as a first-line treatment for Hodgkin’s lymphoma.
The results of this study were presented at the annual meeting of the European Society of Hematology (EHA 2022) held in Austria from June 9 to 12.
A study showing the effectiveness of ADCETRIS added to existing chemotherapy in the treatment of advanced Hodgkin’s lymphoma was published in the ECHELON-1 phase 3 clinical trial published in NEJM in 2018.
At that time, ADCETRIS + doxorubin + vincristine + dicarbazine group (A + AVD) showed benefits in long-term progression-free survival (PFS) than doxorubin + bleomycin + vinblastine + dacarbazine group (ABVD). appear.
The results of this study are six-year follow-up data.
Professor John Radford’s research team at the University of Manchester, UK conducted an open-label clinical trial by randomly placing 1334 patients into A+AVD group (n=664) and ABVD group (n=670). The study enrolled patients with stage 3 or 4 Hodgkin’s lymphoma.
The follow-up period of the study was 6.1 years (73 months, median).
As a result of the study, the risk of death in the A+AVD group was reduced by 41% compared to the ABVD group.
Overall survival (OS) events were significantly lower in the A+AVD group as 39 and ABVD group as 64, and the OS rates were analyzed as 93.9% and 89.4% (P=0.009), respectively.
Importantly, after two cycles of chemotherapy, OS benefits were maintained in the subgroups of patients with PET-negative or PET-positive, including those with stage III and IV Hodgkin’s lymphoma.
In particular, the OS benefit of the A+AVD group was maintained in the multivariate analysis with demographics and disease factors corrected at the baseline. In addition, the PFS benefit ratio at 6 years remained significantly better in the A+AVD group (82.3% vs 74.5%; HR, 0.68).
The long-term safety profiles of the two groups were similar, and there were no new safety concerns.
At 2nd year, peripheral neuropathy occurred in 67% of the A+AVD group and 42% of the ABVD group, but most of the numbness in the hands and feet was recovered in some patients.
The research team said, “This study is meaningful in that it is the first study that directly compared the A+AVD group and the ABVD group to confirm the OS benefit.” It can be considered as a first-line treatment option for patients with lymphoma.”
